The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The expansion makes Exothera one of the largest viral vector facilities in Europe
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Subscribe To Our Newsletter & Stay Updated
